Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ST Pharm Co.,Ltd. (237690.KQ)
Seoul, KR
Operating as a Contract Development and Manufacturing Organization (CDMO), ST Pharm Co. Ltd. provides pharmaceutical and non-pharmaceutical products within South Korea. Its comprehensive Chemistry, Manufacturing, and Controls (CMC) services include the development of analytical methods, in-house reference standard testing, qualification and validation of analytical techniques, detailed analytical characterization, and robust CMC documentation. The company also specializes in oligonucleotide-based products, such as antisense oligonucleotides, siRNA, miRNA, aptamers, CpG, and decoy molecules, as well as monomers and phosphoramidites. Additionally, ST Pharm manufactures generic Active Pharmaceutical Ingredients (APIs) for a broad range of therapeutic areas, including anti-cancer, anti-coagulant, anti-fungal, anti-hyperlipidemia, anti-hypertensive, anti-tuberculosis, asthma, COPD, cough suppression, diabetes mellitus, epilepsy, hepatitis B, and erectile dysfunction medications, along with ingredients for MRI contrast agents. Beyond its pharmaceutical focus, the firm supplies components for secondary batteries, electronic materials, and polymer catalysts. Founded in 1983 as Samchully Pharmaceutical Company Ltd., ST Pharm Co. Ltd. is headquartered in Seoul, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.96% | -6.22% | -12.07% | -11.95% | +14.62% | +16.61% | +69.32% | +55.93% | +17.73% | +174.80% | +174.80% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 7 | +2 |
| Hold | 0 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +9.5%+21.1% ★ Q1'26: +27.7% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +18.1%+51.0% ★ Q1'26: +1,290.4% (vs Q1'25)
-
FCF margin Medical - Pharmaceuticals: +29.9%-9.2% Q1'26: +140.7% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +4.8%+16.4% ★ Q1'26: +16.9% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.0%+8.7% ★ Q1'26: +7.9% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: -0.1%+5.4% Q1'26: +6.8% (vs Q1'25)
-
Debt / EBITDA Medical - Pharmaceuticals: -0.11×0.93× ★ Q1'26: 0.94× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 10 EPS Ana. |
Dec 2027 9 Rev. Ana. 9 EPS Ana. |
Dec 2028 3 Rev. Ana. 4 EPS Ana. |
Dec 2029 4 Rev. Ana. 3 EPS Ana. |
Dec 2030 4 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
200.36B
est: 201.40B (-0.5%)
|
202.80B
est: 199.30B (+1.8%)
|
97.74B
est: 114.50B (-14.6%)
|
93.26B
est: 93.20B (+0.1%)
|
124.11B
est: 138.00B (-10.1%)
|
165.64B
est: 163.50B (+1.3%)
|
249.32B
est: 225.70B (+10.5%)
|
284.99B
est: 282.09B (+1.0%)
|
273.75B
est: 286.36B (-4.4%)
|
331.55B
est: 329.14B (+0.7%)
|
412.82B
401.22B – 424.07B
+25.4% YoY
|
500.06B
442.85B – 594.83B
+21.1% YoY
|
601.71B
556.47B – 671.38B
+20.3% YoY
|
765.90B
708.31B – 854.58B
+27.3% YoY
|
923.80B
854.34B – 1.03T
+20.6% YoY
|
| EBITDA |
92.53B
est: 29.41B (+214.6%)
|
70.88B
est: 29.10B (+143.6%)
|
-6.42B
est: 16.72B (-138.4%)
|
-13.71B
est: 13.61B (-200.7%)
|
-2.11B
est: 20.15B (-110.5%)
|
20.83B
est: 23.87B (-12.7%)
|
39.71B
est: 32.95B (+20.5%)
|
52.49B
est: 41.19B (+27.4%)
|
76.07B
est: 57.37B (+32.6%)
|
84.40B
est: 65.94B (+28.0%)
|
82.70B
80.37B – 84.95B
+25.4% YoY
|
100.18B
88.72B – 119.16B
+21.1% YoY
|
120.54B
111.47B – 134.49B
+20.3% YoY
|
153.43B
141.89B – 171.20B
+27.3% YoY
|
185.06B
171.15B – 206.49B
+20.6% YoY
|
| EBIT |
81.74B
est: 11.47B (+612.5%)
|
59.31B
est: 11.35B (+422.4%)
|
-15.65B
est: 6.52B (-339.9%)
|
-24.89B
est: 5.31B (-568.9%)
|
-16.18B
est: 7.86B (-305.8%)
|
6.42B
est: 9.31B (-31.1%)
|
22.10B
est: 12.86B (+71.9%)
|
29.46B
est: 16.07B (+83.3%)
|
50.49B
est: 33.20B (+52.1%)
|
54.52B
est: 38.16B (+42.9%)
|
47.86B
46.51B – 49.16B
+25.4% YoY
|
57.97B
51.34B – 68.96B
+21.1% YoY
|
69.75B
64.51B – 77.83B
+20.3% YoY
|
88.79B
82.11B – 99.07B
+27.3% YoY
|
107.09B
99.04B – 119.50B
+20.6% YoY
|
| Net Income |
61.43B
est: 70.48B (-12.8%)
|
45.00B
est: 49.95B (-9.9%)
|
-9.27B
est: 5.99B (-254.8%)
|
-18.53B
est: -19.15B (+3.3%)
|
-12.15B
est: -15.72B (+22.7%)
|
3.31B
est: 7.44B (-55.5%)
|
18.00B
est: 18.57B (-3.0%)
|
19.58B
est: 25.55B (-23.4%)
|
34.71B
est: 40.42B (-14.1%)
|
54.99B
est: 49.12B (+12.0%)
|
69.06B
56.12B – 86.24B
+40.6% YoY
|
93.16B
74.32B – 114.73B
+34.9% YoY
|
120.25B
108.49B – 138.35B
+29.1% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| SGA |
3.32B
est: 21.85B (-84.8%)
|
2.99B
est: 21.62B (-86.2%)
|
3.78B
est: 12.42B (-69.5%)
|
3.32B
est: 10.11B (-67.1%)
|
4.67B
est: 14.97B (-68.8%)
|
27.89B
est: 17.74B (+57.2%)
|
40.28B
est: 24.49B (+64.5%)
|
9.78B
est: 30.61B (-68.0%)
|
11.08B
est: 25.36B (-56.3%)
|
12.60B
est: 29.14B (-56.8%)
|
36.55B
35.53B – 37.55B
+25.4% YoY
|
44.28B
39.21B – 52.67B
+21.1% YoY
|
53.28B
49.27B – 59.45B
+20.3% YoY
|
67.82B
62.72B – 75.67B
+27.3% YoY
|
81.80B
75.65B – 91.27B
+20.6% YoY
|
| EPS |
3,861.10
est: 3,613.40 (+6.9%)
|
2,421.53
est: 2,561.25 (-5.5%)
|
-496.78
est: 307.00 (-261.8%)
|
-993.18
est: -982.00 (-1.1%)
|
-651.11
est: -806.00 (+19.2%)
|
177.50
est: 381.50 (-53.5%)
|
957.00
est: 951.91 (+0.5%)
|
1,041.07
est: 1,310.21 (-20.5%)
|
1,780.00
est: 1,965.59 (-9.4%)
|
2,705.98
est: 2,388.69 (+13.3%)
|
3,358.50
2,729.20 – 4,194.30
+40.6% YoY
|
4,530.67
3,614.37 – 5,579.84
+34.9% YoY
|
5,848.04
5,276.41 – 6,728.33
+29.1% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-15 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-14 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-13 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-10 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dong-Ryul Lee | Head of Management Support Division & Inside Director | — | male |
| Geun-Jo Im | Chief Executive Officer & Director | — | male |
| Jung-Young Seok | MD & Chief of Quality Assurance Office | — | male |
| Kyeong Eun Jung | Senior MD & GM of Oligo Research Department | — | — |
| Kyeong-Jin Kim | Research Director & Inside Director | — | — |
| Seok-Woo Choi | MD & GM of Sales 1st Department | — | male |
| Soon-Gi Jang | MD & Banwol 1st Factory Mang. | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 237690.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
